Hi Sally,
That is a difficult question because the researcher report that increased blasts and fibrosis in MDS patients can depend on the disease. That is true of cause. The latest reports from ASH 2011 tell us that Nplate has a positive effect in MDS.
The same year FDA wrote "
On 18 February 2011, the independent Data Monitoring Committee (DMC) for a randomised clinical study of Nplate in MDS patients with thrombocytopenia recommended to discontinue Nplate in all patients due to the increased risk of progression to AML. In this study, there were numerically more subjects in the Nplate arm with disease progression to AML (placebo 2, Nplate 9) and with increases in circulating blasts >10% (placebo 3, Nplate 25). The randomisation was 2 to1, Nplate to placebo. Of the cases of MDS disease progression to AML that were observed, patients with RAEB-1 classification of MDS at baseline were more likely to have disease progression to AML compared to lower risk.
"http://www.imb.ie/images/uploaded/do...22.09.2011.pdf
I still hope Promacta will function better for us.
Kind regards
Birgitta-A